Pharma Journalist 8887 posts 0 comments

Eli Lilly and Company has reported positive topline results from its novel TOGETHER-PsA Phase 3b trial, demonstrating that the concomitant use of Taltz (ixekizumab) and Zepbound…
Read More...

Amgen has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom, in a deal valued at up to $840 million. The…
Read More...

Octapharma USA has received approval from the U.S. Food and Drug Administration for a new 2-gram presentation of Fibryga®, a human plasma-derived fibrinogen concentrate, expanding…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...

Takeda Pharmaceutical Company has entered into a global collaboration and license agreement with Halozyme Therapeutics to use Halozyme’s proprietary ENHANZE® drug delivery technology…
Read More...

Eli Lilly and Company has agreed to acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, strengthening Lilly’s pipeline in inflammation-driven…
Read More...

Day One Biopharmaceuticals has completed its acquisition of Mersana Therapeutics, marking a significant expansion of its oncology pipeline and reinforcing its strategy to advance…
Read More...

Protara Therapeutics, Inc., a clinical-stage biotechnology company focused on cancer and rare diseases, has received multiple regulatory boosts from the U.S. Food and Drug…
Read More...

China’s drug regulator has expanded treatment options for patients with rare, genetically driven cancers by approving Zai Lab Limited’s AUGTYRO™ (repotrectinib) for adult patients with…
Read More...

Outlook Therapeutics has received a setback in its efforts to bring an FDA-approved bevacizumab treatment for retinal disease to the U.S. market. The company announced that the U.S.…
Read More...